Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Biogen Inc (BIIB) vs LYFT Inc (LYFT) Price & Performance

Biogen IncTrade

Price performance (Past 24H)

Key statistics

Biogen Inc vs LYFT Inc — how do they compare? Biogen Inc trades at $202.7 (market cap $30.13B), while LYFT Inc trades at $17.5 (market cap $6.64B). The key difference: Biogen Inc is far larger — about 4.5× LYFT Inc's market cap, and Biogen Inc is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals.

BIIBLYFT
Market Cap
$30.13B$6.64B
Sector
HealthIndustrials
52-Week High
$216.63$24.57
52-Week Low
$128.93$12.65
Enterprise Value
$37.20B$6.11B

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Read more on BIIB

About LYFT Inc

Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.

Read more on LYFT